InsiderTrades.com logo

ALZN Insider Trading

Insider Ownership Percentage: 1.39%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,222,946.02

Alzamend Neuro Insider Trading History Chart

This chart shows the insider buying and selling history at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Share Price & Price History

Current Price: $1.50
Price Change: ▼ Price Decrease of -0.43 (-22.28%)
As of 03/26/2026 05:00 PM ET

This chart shows the closing price history over time for ALZN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Alzamend Neuro Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2025Milton C. Ault IIIDirectorSell1,851$2.07$3,831.57View SEC Filing Icon  
12/19/2025William B HorneDirectorSell3,333$2.12$7,065.96View SEC Filing Icon  
10/23/2025Lynne Fahey McgrathDirectorSell30$2.29$68.7025View SEC Filing Icon  
10/9/2025Milton C. Ault IIIDirectorSell20,397$2.32$47,321.048,260View SEC Filing Icon  
10/8/2025Milton C. Ault IIIDirectorSell101,394$2.44$247,401.3628,657View SEC Filing Icon  
10/7/2025Milton C. Ault IIIDirectorSell57,379$2.49$142,873.7168,848View SEC Filing Icon  
10/6/2025Milton C. Ault IIIDirectorSell82,033$2.45$200,980.8526,227View SEC Filing Icon  
10/3/2025Milton C. Ault IIIDirectorSell65,903$2.44$160,803.328,260View SEC Filing Icon  
10/2/2025Milton C. Ault IIIDirectorSell20,686$2.39$49,439.5474,163View SEC Filing Icon  
10/1/2025Milton C. Ault IIIDirectorSell36,777$2.35$86,425.9594,849View SEC Filing Icon  
9/30/2025Milton C. Ault IIIDirectorSell3,566$2.33$8,308.7831,626View SEC Filing Icon  
9/29/2025Milton C. Ault IIIDirectorSell38,324$2.31$88,528.4435,192View SEC Filing Icon  
9/26/2025Milton C. Ault IIIDirectorSell37,738$2.31$87,174.7873,516View SEC Filing Icon  
9/25/2025Milton C. Ault IIIDirectorSell14,628$2.31$33,790.6811,254View SEC Filing Icon  
9/24/2025Milton C. Ault IIIDirectorSell39,140$2.31$90,413.4025,882View SEC Filing Icon  
9/23/2025Milton C. Ault IIIDirectorSell43,238$2.38$102,906.4465,022View SEC Filing Icon  
9/19/2025Milton C. Ault IIIDirectorSell77,009$2.35$180,971.158,260View SEC Filing Icon  
9/18/2025Milton C. Ault IIIDirectorSell20,870$2.47$51,548.9085,269View SEC Filing Icon  
9/17/2025Milton C. Ault IIIDirectorSell2,121$2.45$5,196.45106,139View SEC Filing Icon  
7/31/2025Milton C. Ault IIIDirectorSell100,000$2.22$222,000.008,260View SEC Filing Icon  
7/30/2025Milton C. Ault IIIDirectorSell29,449$2.51$73,916.99108,260View SEC Filing Icon  
7/28/2025Milton C. Ault IIIDirectorSell8,311$2.68$22,273.4837,709View SEC Filing Icon  
7/25/2025Milton C. Ault IIIDirectorSell36,532$2.90$105,942.8046,020View SEC Filing Icon  
7/24/2025Milton C. Ault IIIDirectorSell9,621$2.93$28,189.5382,552View SEC Filing Icon  
7/23/2025Milton C. Ault IIIDirectorSell59,516$2.95$175,572.2092,173View SEC Filing Icon  
3/26/2025William B HorneDirectorBuy370$8.91$3,296.703,333View SEC Filing Icon  
3/20/2025William B HorneDirectorBuy555$8.82$4,895.102,962View SEC Filing Icon  
3/18/2025Milton C. Ault IIIDirectorBuy555$8.64$4,795.209,152View SEC Filing Icon  
3/12/2025Milton C. Ault IIIDirectorBuy11$6.12$67.328,596View SEC Filing Icon  
8/6/2024Milton C. Ault IIIDirectorBuy8$24.75$198.008,585View SEC Filing Icon  
7/31/2024Milton C. Ault IIIDirectorBuy2$33.66$67.328,577View SEC Filing Icon  
4/19/2024Milton C. Ault IIIDirectorBuy11$62.10$683.108,574View SEC Filing Icon  
4/1/2024Milton C. Ault IIIDirectorBuy3$81.90$245.708,563View SEC Filing Icon  
1/5/2024Milton C. Ault IIIDirectorBuy55$91.80$5,049.008,537View SEC Filing Icon  
12/26/2023Milton C. Ault IIIMajor ShareholderBuy5$81.00$405.00289View SEC Filing Icon  
12/22/2023Milton C. Ault IIIMajor ShareholderBuy2$82.80$165.601,854View SEC Filing Icon  
9/26/2023David J KatzoffCFOBuy39$256.50$10,003.5060View SEC Filing Icon  
5/24/2023Milton C. Ault IIIMajor ShareholderBuy13$796.50$10,354.50283View SEC Filing Icon  
4/28/2023Stephan JackmanCEOBuy27$729.00$19,683.0033View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Alzamend Neuro (NASDAQ:ALZN)

49.61% of Alzamend Neuro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALZN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alzamend Neuro Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/12/2026DRW Securities LLC116,319$0.21M0.0%+27.5%3.059%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC27,506$50K0.0%+33.7%0.723%Search for SEC Filing on Google Icon
2/17/2025Citadel Advisors LLC30,638$36K0.0%N/A0.564%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC33,540$39K0.0%N/A0.618%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC26,482$26K0.0%N/A0.385%Search for SEC Filing on Google Icon
2/2/2024Truist Financial Corp154,327$0.14M0.0%-93.3%2.168%Search for SEC Filing on Google Icon
5/11/2022RFG Advisory LLC250,000$0.31M0.0%N/A0.277%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087%Search for SEC Filing on Google Icon
4/22/2022Truist Financial Corp2,314,907$2.85M0.0%N/A2.569%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC116,666$0.22M0.0%N/A0.131%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More on Alzamend Neuro

Today's Range

Now: $1.50
Low: $1.46
High: $1.91

50 Day Range

MA: $2.01
Low: $1.50
High: $2.43

52 Week Range

Now: $1.50
Low: $1.46
High: $9.90

Volume

2,202,816 shs

Average Volume

114,489 shs

Market Capitalization

$5.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Alzamend Neuro?

Alzamend Neuro's top insider shareholders include:
  1. Milton C Ault III (Director)
  2. Milton C Ault III (Major Shareholder)
  3. William B Horne (Director)
  4. David J Katzoff (CFO)
  5. Mark Gustafson (Director)
  6. Stephan Jackman (CEO)
  7. Lynne Fahey Mcgrath (Director)
  8. L Mary Smith (Insider)
Learn More about top insider investors at Alzamend Neuro.

Who are the major institutional investors of Alzamend Neuro?

Alzamend Neuro's top institutional shareholders include:
  1. DRW Securities LLC — 3.06%
  2. Geode Capital Management LLC — 0.72%
Learn More about top institutional investors of Alzamend Neuro stock.

Which institutional investors are buying Alzamend Neuro stock?

During the previous quarter, ALZN stock was purchased by institutional investors including:
  1. DRW Securities LLC
  2. Geode Capital Management LLC
In the last year, these company insiders have bought Alzamend Neuro stock:
  1. Milton C Ault III (Director)
  2. Milton C Ault III (Major Shareholder)
Learn More investors buying Alzamend Neuro stock.

Alzamend Neuro Active Insiders

Mark Gustafson
Mark Gustafson
Director
L. Mary Smith
Insider
Milton C Ault III
Milton C Ault III (Age 56)
Major Shareholder
10 recent trades